Isofol is a clinical-stage biotechnology company dedicated to improving outcomes for patients with difficult-to-treat cancers. The company’s drug candidate, arfolitixorin, is a next-generation folate therapy designed to enhance the efficacy of established standard treatments for solid tumors. Arfolitixorin is initially and currently being evaluated in a Phase Ib/II clinical trial in metastatic colorectal cancer, the second leading cause of cancer-related death worldwide and an area of significant unmet medical need. Isofol is listed on Nasdaq Stockholm.

Isofol's pitch will demonstrate why optimizing today's and tomorrow's first-line colorectal cancer treatment represents one of the largest opportunities to improve patient outcomes. The presentation will also discuss arfolitixorin's market potential and why Isofol offers an attractive investment proposition.